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Antigen Selection of Anti-DSG1 Autoantibodies
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Foliaceus
Ye Qian1, Stephen H. Clarke2, Valeria Aoki3, Gunter Hans-Filhio4, Evandro A. Rivitti3 and Luis A. Diaz1
for the Cooperative Group on Fogo Selvagem Research
Fogo selvagem (FS), the endemic form of pemphigus foliaceus (PF), is characterized by pathogenic anti-
desmoglein 1 (DSG1) autoantibodies. To study the etiology of FS, hybridomas that secrete either IgM or IgG
(predominantly IgG1 subclass) autoantibodies were generated from the B cells of eight FS patients and one
individual 4 years before FS onset, and the H and L chain V genes of anti-DSG1 autoantibodies were analyzed.
Multiple lines of evidence suggest that these anti-DSG1 autoantibodies are antigen selected. First, clonally
related sets of anti-DSG1 hybridomas characterize the response in individual FS patients. Second, H and L chain
V gene use seems to be biased, particularly among IgG hybridomas, and third, most hybridomas are mutants
and exhibit a bias in favor of CDR (complementary determining region) amino acid replacement (R) mutations.
Strikingly, pre-FS hybridomas also exhibit evidence of antigen selection, including an overlap in VH gene use
and shared multiple R mutations with anti-DSG1 FS hybridomas, suggesting selection by the same or a similar
antigen. We conclude that the anti-DSG1 response in FS is antigen driven and that selection for mutant anti-
DSG1 B cells begins well before the onset of disease.
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INTRODUCTION
Pemphigus encompasses a group of autoimmune blistering
diseases exhibiting pathogenic autoantibodies against
desmogleins (DSG), a family of desmosomal cell adhesion
glycoproteins (Lever, 1953; Beutner and Jordon, 1964;
Ding et al., 1997; Udey and Stanley, 1999). The hallmark
of these diseases is the presence of intraepidermal
vesicles (Lever, 1953) and anti-epidermal autoantibodies
(Beutner and Jordon, 1964; Ding et al., 1997; Udey and
Stanley, 1999). Pemphigus foliaceus (PF) and pemphigus
vulgaris (PV) are the two major phenotypes of pemphigus
(Lever, 1953). Immunologically, the sera of PF patients show
anti-DSG1 antibodies, whereas the sera of PV patients
contain antibodies against DSG3 (mPV), or both DSG1 and
DSG3 (mcPV) (Ding et al., 1997; Udey and Stanley, 1999).
PV and PF in North America are sporadic (Lever, 1953; Udey
and Stanley, 1999), but endemic PF is described in certain
states of Brazil, where it is known as fogo selvagem (FS) (Diaz
et al., 1989b). FS shows similar clinical, histological, and
immunological features to those observed in non-endemic PF
(Stanley et al., 1986; Diaz et al., 1989a). The published
epidemiological studies of FS strongly suggest that this
disease is precipitated by environmental agent(s) harbored
in certain regions of Brazil. One of these sites, under
investigation by our group for the last 15 years, is the
Amerindian Reservation of Limao Verde (Hans-Filho et al.,
1996). We have reported the serological transition from
preclinical to clinical stage of FS in several cases from Limao
Verde (Warren et al., 2000, 2003; Li et al., 2003; Qaqish
et al., 2009).
Fogo selvagem is mediated by pathogenic autoantibodies
against DSG1 (Roscoe et al., 1985; Stanley et al., 1986).
These pathogenic autoantibodies are IgG4 restricted (Rock
et al., 1989) and their appearance in the serum heralds the
onset of clinical disease (Warren et al., 2003). In fact, a recent
study by our group has identified IgG4 anti-DSG1 auto-
antibodies as the serological markers of disease in FS (Qaqish
et al., 2009). Non-pathogenic IgG anti-DSG1 autoantibodies
(Warren et al., 2000; Li et al., 2003) and IgM anti-DSG1
autoantibodies (Diaz et al., 2008) have been detected in
healthy individuals living in endemic areas of FS. The under-
lying mechanism of autoantibody formation in FS, however,
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specifically that of anti-DSG1 autoantibodies, is still poorly
understood. Whether these autoantibodies are developed
through a polyclonal activation or an antigen-driven
mechanism is still a mystery, but this information is needed
to identify the cause of FS. To provide a definite answer to
this question requires the genetic analysis of anti-DSG1
autoantibody gene repertoire.
Analyses of the V gene sequences encoding the auto-
antibodies in PV by our group (Qian et al., 2007) and by
Payne et al. (2005) have yielded important clues to the
development of anti-DSG1 and anti-DSG3 antibodies. The
potentially pathogenic IgG anti-DSG response in PV has been
shown to be antigen selected (Qian et al., 2007). The results
of these studies are similar to the findings reported in other
autoimmune diseases, such as systemic lupus erythematosus
and rheumatoid arthritis. Recently, two single-chain variable
fragments of pathogenic autoantibodies from a PF patient
were isolated and the H chain V regions of the autoantibodies
from this patient were shown to be encoded by a restricted
number of genes (Ishii et al., 2008).
Although there has been no genetic study on the auto-
antibodies in individuals before the onset of autoimmune
diseases, the high prevalence of FS in Limao Verde provides
us with a unique opportunity to address this question, as we
have preserved peripheral blood mononuclear cells (PBMCs)
of selected FS and healthy individuals from this human
settlement. In this study, we have examined anti-DSG B cells
from multiple FS patients and from an individual who was
healthy at the time of the blood draw, but developed FS
4 years later. We conclude that (a) anti-DSG response in FS is
composed of mutant B cells that have been subject to
extensive antigen selection, and (b) the pre-clinical anti-DSG
response is composed of mutant B cells that have undergone
the same or similar selection pressures. These findings
indicate the presence of inciting antigen(s) in FS endemic
areas, and these inciting antigen(s) have an important role in
the etiology of FS.
RESULTS
Anti-DSG1 in FS patients is oligoclonal
We fused Epstein-Barr virus-transformed PBMCs from eight
FS patients with myeloma cells and screened for the resulting
hybridomas for anti-DSG1 production by ELISA. We gene-
rated 78 anti-DSG1 hybridomas, 40 IgM producers, and 38
IgG producers (Table 1). Most IgG anti-DSG1 hybridomas
were IgG1. Despite the fact that the IgG4 autoantibodies are
the main pathogenic antibodies in the sera of FS patients
(Rock et al., 1989), only two IgG4 hybridomas were
identified from two FS patients. There are possible explana-
tions for the disparity between the high levels of serum IgG4
from FS patients and the low frequency of IgG4 hybridomas
generated in this study. First, serum IgG4 antibodies were
produced by plasma cells. Plasma cells reside mainly in the
tissues and bone marrow, and are rarely present in peripheral
blood (Benner et al., 1981; Slifka and Ahmed, 1996). Thus,
they were not abundantly present in the FS patients’ blood
samples collected. Second, Epstein-Barr virus transformation
predominantly immortalizes B cells (Middleton et al., 1991),
and the IgG4-secreting plasma cells might not be immor-
talized and thus might be absent from the subsequent
hybridoma generation. Third, this may simply reflect the
relative amount of IgG1- and IgG4-expressing B cells in the
peripheral blood of FS patients. The DSG1 specificity of the
antibodies produced by these hybridomas was confirmed by
immunoprecipitation (Figure 1a) and indirect immunofluor-
escence (Figure 1b). Most of these hybridomas (35 of 38) also
recognized the ectodomain of DSG3 by ELISA (data not
shown).
The mRNA of the expressed VH and VL genes of these 77
anti-DSG1 hybridomas was PCR amplified and sequenced to
determine VH and VL gene use and to identify somatic
mutations. Table 1 summarizes this analysis. Clonally related
sets of hybridomas from an individual fusion are a hallmark of
secondary responses to foreign antigen and are also a
characteristic of autoimmune responses, including those in
human PV, as we have shown previously (Qian et al., 2007).
This oligoclonality is because of the antigen-driven clonal
expansion of a limited number of B-cell clones. Clonally
related hybridomas express the identical V region genes and
have identical VH CDR3 sequences. By these criteria, we
identified 12 sets of clonally related hybridomas from seven
of the eight FS patients. In patient FS8, all seven of the anti-
DSG1 hybridomas identified belonged to a single clonal set,
whereas those from patients FS12 and FGS belonged to only
two clonal sets each, indicating the dominance of a small
number of clones in some patients. Most clonally related
hybridomas were identical in sequence, suggesting that a
limited number of clones in each patient had undergone
extensive clonal growth in the absence of somatic mutation.
However, sequence identity raises the possibility that the
presence of clonal sets is an artifact of in vitro growth. To
discriminate between these possibilities, we compared the
extent of somatic mutation among the clonal sets before
divergence with that of singlet hybridomas. On the basis of
sequence comparison with the most similar germline VH
genes, most (9 of 11) clonally related sets had at least 10
differences from germline, indicating the occurrence of
extensive somatic mutation before clonal divergence. This
was significantly different from that of singlet hybridomas, in
which only half had 10 or more mutations (16 of 35) (w2,
P¼0.036). This argues against an in vitro artifact to explain
the presence of clonal sets in FS patients, as any in vitro
expansion will be independent of the extent of somatic
mutation. This is further suggested by intraclonal sequence
difference in the clonal set from patient FS12 (FS12-1F10 and
FS12-3A7). Thus, the presence of clonal sets of hybridomas in
these FS patients likely reflects in vivo clonal expansion,
presumably because of the selective advantage in antigen
binding conferred by the somatic mutations they acquired
before clonal divergence.
We identified 18 VH genes used by 48 clonally indepen-
dent anti-DSG1 hybridomas (Table 1 and Figure 2a upper
panels) and found that IgM and IgG anti-DSG1 hybridomas
differed significantly in their expressed VH repertoires. The
VH3 gene family use increased from 43.5% among IgM
hybridomas to 68.2% (w2, P¼0.095) among IgG hybridomas,
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Table 1. Anti-desmoglein 1 (Dsg1) hybridomas from fogo selvagem (FS) patients
FWRs CDRs
PBMC Clones1 Isotype VH Similarity R
2 S3 P4(FWRs) R S P(CDRs) JH CDR3
FS6 FS6-1D10 IgM IGHV3-48*02 98.3 1 0 0.06073 4 0 0.00262 IGHJ4*02 DSGYNTFDY
FS6-2C12 IgG1 IGHV4-59*01 90.0 9 8 0.00311 9 3 0.04149 IGHJ5*02 QNCSPNSCFNYFAP
FS6-2F5(6) IgM IGHV3-23*01 94.2 8 7 0.19667 2 0 0.70918 IGHJ4*02 LIDGGY
FS6-2G3 IgG1 IGHV3-23*01 92.2 5 5 0.00031 12 1 0.00010 IGHJ6*02 EMSLQPVAGMDV
FS6-3A4(2) IgG1 IGHV1-69*01 94.9 3 7 0.00359 3 1 0.33725 IGHJ6*03 GRFYHMDV
FS6-3D7 IgM IGHV1-18*01 95.9 4 2 0.05007 5 1 0.03033 IGHJ4*02 DLGGTYFDY
FS6-4A3 IgM IGHV4-4*07 100.0 IGHJ6*03 DRGVGYCSSTSCYSGRYMDV
FS6-4D4 IgM IGHV1-3*01 96.6 7 2 0.76103 0 1 0.93314 IGHJ4*02 HYYDSSGYYDNFDY
FS6-5B7 IgM IGHV2-5*05 98.3 3 2 0.53435 0.81007 IGHJ4*02 STGAARTDNTYYFDY
FS7 FS7-1C11 IgG1 IGHV5-51*01 97.0 3 2 0.03761 5 0 0.01121 IGHJ4*02 HRIGYCSGSNCYDFDY
FS7-1H10 IgG2 IGHV1-18*01 91.3 6 9 0.00038 5 5 0.38273 IGHJ4*02 HFIPAPPDY
FS7-2A9 IgG1 IGHV3-23*02 95.2 2 3 0.00065 8 1 0.00054 IGHJ4*02 RDIYGDVGVGLVDY
FS7-2F8(4) IgG1 IGHV3-7*01 91.5 8 6 0.01155 9 1 0.01347 IGHJ4*02 TESATIFGVAYYYFDY
FS7-2G6 IgM IGHV3-23*01 95.3 5 3 0.05574 3 3 0.33725 IGHJ3*02 DPGAPCSTTNCYVSDAFDM
FS7-4C1 IgG1 IGHV3-23*01 96.6 3 1 0.04677 5 1 0.01110 IGHJ6*03 DSDSHYYMDV
FS7-4H7 IgM IGHV5-51*01 95.2 5 2 0.04332 5 2 0.05366 IGHJ4*02 GGEAYNLDY
FS8 FS8-1A9(7) IgM IGHV4-59*01 96.6 3 3 0.05258 2 2 0.40536 IGHJ6*03 GVYYGSGGYYGGGSYYYMDV
FS12 FS12-1D2(2) IgG1 IGHV3-7*01 96.3 2 2 0.00558 3 4 0.23564 IGHJ4*02 DSLTAYCGGDCPTVTFGY
FS12-1F10(2) IgG1 IGHV3-74*01 99.0 0 1 0.03950 2 0 0.04735 IGHJ3*02 AYYDFWSGHDDAFDI
FS12-3A7 IgG1 IGHV3-74*01 99.3 0 1 0.09205 1 0 0.18335 IGHJ3*02 AYYDFWSGHDDAFDI
FS33 FS33-1A9 IgM IGHV1-46*01 100.0 IGHJ3*02 DRPDSSGYYLGAFDI
FS33-1B8(4) IgM IGHV3-7*01 98.6 0 2 0.01657 2 0 0.09153 IGHJ6*04 DRQGIYYYYGLDV
FS33-1D4(2) IgM ND
FS33-2B12 IgG1 IGHV3-48*03 91.8 9 9 0.02832 5 1 0.35950 IGHJ5*02 GLPYSGSDRGLDP
FS33-2C6 IgG1 IGHV3-13*01 97.9 3 0 0.36241 3 0 0.03787 IGHJ4*02 RRVIRVRGVIPFFDY
FS33-2E6(4) IgG1 IGHV3-11*03 90.1 8 8 0.00121 9 3 0.04319 IGHJ4*02 GIDYYDSSGHYGSWGEDR
FS33-2F4 IgG1 IGHV4-39*06 96.6 3 1 0.03664 7 0 0.00080 IGHJ4*02 DWGTGWQPLNYFDY
FS33-3C6 IgM IGHV1-3*01 98.3 2 1 0.22538 2 0 0.13601 IGHJ4*02 STRITMITSGY
FS33-3C7 IgG1 ND
FS33-3E5 IgM IGHV1-46*01 96.6 4 1 0.13579 3 2 0.18203 IGHJ4*02 DPGRGAAGIGYYFDY
FS33-3H3 IgM IGHV3-30*18 97.0 2 1 0.02074 4 2 0.03590 IGHJ6*02 ERTVATLYHYYYYGMDV
FS33-4D4(2) IgM IGHV1-3*01 89.1 12 8 0.01015 8 4 0.16514 IGHJ5*02 NQQQLEQQNWYVP
FS33-4G10 IgM IGHV1-69*01 99.7 0.21008 0 1 0.58756 IGHJ4*02 SGYDFYSADY
FS33-5E11 IgM IGHV1-46*01 100.0 IGHJ3*02 DRPDSSGYYLGAFDI
FS33-5F5 IgG1 IGHV5-51*01 99.0 0 1 0.03400 2 0 0.04351 IGHJ4*02 RTMATITGPIGY
FS33-5F7 IgM IGHV3-73*02 98.7 2 1 0.39825 0 1 0.77521 IGHJ5*02 GRDGTVVSLGST
GCDS GCDS-1C2(2) IgG1 IGHV3-23*01 95.6 4 4 0.03017 4 1 0.12097 IGHJ4*02 RRFDWLLYFDY
GCDS-2A8 IgG1 IGHV3-11*01 95.9 2 2 0.00276 7 1 0.00127 IGHJ6*03 DGRGYNYNYNRYFYYMDV
Table 1 continued on the following page
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and VH1 gene family use decreased from 34.8 to 9.1%
(w2, P¼0.038). No VH gene dominated the IgM repertoire,
but IGHV3-23 may be favored in the IgG repertoire, as it was
used by 5 of 22 clonally independent IgG hybridomas,
although this does not reach the level of significance in
comparison with IgM hybridomas (2 of 23 clonally inde-
pendent hybridomas: w2, P¼ 0.1942) (Figure 2a upper panels)
or with healthy controls (12 of 71 B cells; w2, P¼0.5367)
(Brezinschek et al., 1995). JH use by IgM and IgG anti-DSG1
included JH3, 4, 5, and 6, and was not significantly different
between IgM and IgG hybridomas, and not different from
healthy control B cells (Brezinschek et al., 1995). In addition,
we observed no restriction in VH CDR3 length, as it ranged
from 6 to 21 amino acids (Table 1).
We identified 11 k and 6 l VL genes used by 29 sequenced
clonally independent anti-DSG1 hybridomas (12 IgM and 17
IgG) (Table 2 and Figure 2b upper panels). As with VH gene
use, VL gene use seems to be more restricted among IgG
hybridomas than among IgM hybridomas. With one exception,
each IgM hybridoma expressed a unique VL gene, whereas
four VL genes were used by two or more clonally independent
IgG hybridomas. IGKV1D-39 was expressed by four of 17
independent hybridomas (23.5%), suggesting that this VL gene
provides a selective advantage in binding DSG. This biased
distribution of VL is similar to that observed in responses to
foreign antigens and, therefore, suggests that the anti-DSG1 B
cells in FS patients undergo antigen selection.
Antigen selection of mutant anti-DSG1 B cells
The anti-DSG1 hybridomas from FS patients were extensively
mutated (Table 1). The number of VHDJH mutations in IgM
hybridomas (166 mutations in 23 sequences; 7.2 mutations/
gene) was half that in IgG hybridomas (324 mutations in 22
sequences; 14.7 mutations/gene) (w2, P¼ 0.021). Moreover,
all five unmutated sequences were from IgM hybridomas
(Table 1). We used a multinomial distribution model (Lossos
et al., 2000) to determine bias in the frequency of amino acid
replacement (R) and silent (S) mutations in framework regions
(FWRs) and complementary determining regions (CDRs).
We found that 5 of 23 IgM hybridomas showed a biased
distribution of mutations in either FWR- or CDR-encoding
regions and 1 (FS33-3H3) showed a bias distribution in both
FWR- and CDR-encoding regions. In contrast, 15 of 22
independent IgG hybridomas showed a biased distribution in
both FWR- and CDR-encoding regions, and most of the
remaining hybridomas showed a biased distribution in either
FWR- or CDR-encoding regions (Table 1). This difference
between IgM and IgG hybridomas is statistically significant
(w2, Po0.001). We conclude that anti-DSG B cells are
antigen selected, and that mutant IgG B cells in particular
have a selective advantage in contributing to this response in
FS patients.
The expressed VL genes from these hybridomas were also
extensively mutated, although as is typical, VL mutations
were less frequent than VH mutations (195 mutations in
Table 1. Continued
FWRs CDRs
PBMC Clones1 Isotype VH Similarity R
2 S3 P4(FWRs) R S P(CDRs) JH CDR3
GCDS-2D11 IgG4 IGHV2-5*09 97.3 2 2 0.04076 4 0 0.02137 IGHJ4*02 RRLGLRYCSTSSCFGDFDY
GCDS-3G9 IgG1 IGHV3-23*01 96.9 2 3 0.00534 6 0 0.00340 IGHJ4*02 DHCRSDSCYRADL
GCDS-5D2 IgG1 ND
GCDS-6A6 IgG1 ND
GCDS-6G10 IgM IGHV3-30*18 99.3 0 1 0.09014 1 0 0.17838 IGHJ5*02 GLLPEDIVVVPAAQTENWFDP
JLDO JLDO-1B2 IgM IGHV3-48*02 100.0 IGHJ4*02 DSDDYGDYGCFDY
JLDO-2A3 IgM IGHV3-30*03 97.0 3 1 0.08352 3 2 0.13312 IGHJ4*02 EEADFWSGYYFDY
JLDO-3F8 IgG1 IGHV3-30-3*01 98.0 2 1 0.10667 3 0 0.02760 IGHJ6*03 DQQPTIYYYYYMDV
JLDO-3G4 IgM IGHV3-9*01 99.0 1 1 0.23217 1 0 0.26683 IGHJ6*02 DKTLYYYYGMDV
JLDO-4B5 IgG1 IGHV3-73*02 92.6 3 6 0.00002 11 2 0.00040 IGHJ3*02 LIQVWSSQTFDI
FGS FGS-2E5 IgM IGHV4-59*01 100.0 IGHJ6*02 VEVKRDTGTTHPYYYGMDV
FGS-4E4(3) IgG4 IGHV3-48*01 94.2 5 4 0.01181 6 2 0.04083 IGHJ4*02 GRTTFGGEGQLFDY
CDR, complementary determining region; FWR, framework region; ND, not determined; PMBC, peripheral blood mononuclear cell.
1Numbers in parentheses indicate the identical clones isolated from the same patient. Clones with evidence of antigen selection in both FWRs and CDRs are
shown in bold. Clonally related hybridomas are shown with italics.
2Number of replacement mutations.
3Number of silent mutations.
4P-value determined according to Lossos et al. (2000). Those values less than 0.05, which is the indication of antigen selection, are shown in bold. FWRs
include FWR1, FWR2, and FWR3, whereas CDRs include CDR1 and CDR2. The P-values of clones with 100% similarity to germline genes are not
determined.
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29 genes (6.7 mutations/gene) vs 490 mutations in 45 genes
(10.9 mutations/gene) (w2, P¼ 0.055) (Table 2). In common
with the VH mutations in these hybridomas, the frequency of
VL mutation in IgM hybridomas (5.2 mutations/gene) was
lower than that in IgG (7.7 mutations/gene) (w2, P¼0.4434).
However, few IgG VL genes exhibited a bias in the distri-
bution of CDR mutations (2 of 17 VL genes) (Table 2), sugges-
ting that VL mutations are less likely to improve antigen
binding than VH mutations.
Shared mutations among anti-DSG1 autoantibodies
Bias in somatic mutation was also evident by the large
number of shared mutations among these hybridomas
(Figure 3). For example, four of seven IGHV3-23-expressing
hybridomas acquired a mutation at position 31 in the CDR1-
encoding region of this VH (Figure 3) with S31N occurring
twice. In addition, CDR1 mutation S35N occurred twice and
S35T occurred twice, and in CDR2, both A50S and A50G
occurred twice. There were also shared mutations located in
FWRs, such as N77K, Y80F, and M83I. Parallel mutations
were not limited to the more frequently used IGHV3-23 and
IGHV3-30 genes, as they occurred in other VH genes
(Figure 3). Interestingly, S31N occurred in three other
members of the VH1 family, and in a member each of the
VH3 and VH5 families, further suggesting its importance to
antigen binding.
Antigen selection for anti-DSG1 autoantibodies from an
individual at the pre-clinical stage of disease
We have shown that healthy individuals from Limao Verde
possess IgM and IgG anti-DSG1 autoantibodies (Warren
et al., 2000; Diaz et al., 2008), strongly suggesting the
existence of an environmental factor in endemic areas that
sensitizes and triggers anti-DSG1 autoantibody formation in
these individuals. To understand the development of anti-
DSG1 antibodies in FS, we investigated the anti-DSG1
response before the onset of disease. We have collected
serum samples and PBMCs from selected individuals with or
without FS living in endemic regions for the past 20 years,
and one non-FS individual developed FS 4 years later (patient
FS45). The PBMCs of this individual, kept in liquid nitrogen,
were Epstein-Barr virus transformed and fused with MSP-2S
myeloma cells.
We identified 28 anti-DSG1 hybridomas (17 IgM, 11
IgG1) by ELISA (Table 3) and confirmed their specificity by
immunoprecipitation (data not shown). Two clonal sets of
hybridomas were identified, the largest of which consisted of
six IgM hybridomas. A total of 14 VH genes encode anti-
DSG1 antibodies, but only IGHV3-23 and IGHV3-30 were
used by both IgM and IgG hybridomas (Figure 2a lower
panels). IGHV3-30, used by three independent FS IgM
hybridomas, was the most frequently used VH gene by pre-
FS IgG hybridomas (3 of 10 clonally independent pre-FS IgG
hybridomas).
The VL gene use by pre-FS hybridomas (Table 4) was
also diverse, similar to that of FS hybridomas. We identified
only two VL genes used by both pre-FS and FS hybridomas
(Figure 2a lower panels and Figure 2b lower panels). The
IgG hybridomas were very restricted in VL use as five of
the seven clonally independent hybridomas sequenced
used IGKV2D-28 and IGKV4-1 (Figure 2a lower panel).
Interestingly, we did not observe Vl gene use among pre-FS
hybridomas (0 of 17 vs 10 of 29 among FS hybridomas;
w2, P¼ 0.006) (Figure 2b lower panel). Overall, although the
pre-FS and FS anti-DSG1 responses overlap in VH gene use,
they exhibit notable differences in VL gene use.
As with the FS hybridomas, the overall VH and VL mutation
frequencies differ (266 mutations in 20 VH genes; 59
mutations in 17 VL genes; w
2, Po0.001). All VH genes of
pre-FS hybridomas were somatically mutated (Table 3), and
IgM and IgG anti-DSG1 hybridomas exhibited similar muta-
tion rates (123 mutations in 10 genes for IgM; 143 mutations
in 10 genes for IgG; w2, P¼0.7451). These rates were also
similar to those of FS IgG hybridomas (w2, P¼0.6125 and
P¼0.9404, respectively). Multiple pre-FS hybridomas exhi-
bited evidence of antigen selection based on biases in VH R
and S mutations. However, only 3 of 12 clonally independent
IgM hybridomas showed a significant bias, and then only in
FWR-encoding regions, whereas 6 of 10 clonally indepen-
dent IgG hybridomas exhibited a significant bias in mutation
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Figure 1. Anti-desmoglein 1 (DSG1) hybridoma antibodies are specific for
DSG1. (a) Representative anti-DSG1 MAbs (all are IgG1, except FGS-4E4 and
GCDS-2D11 (IgG4)) from different fogo selvagem (FS) patients were used to
immunoprecipitate DSG1. Hybridoma antibodies bound to protein G agarose
beads were used to immunoprecipitate His-tagged DSG1 ectodomain. The
immunoprecipitated samples were used in western blots using an anti-His
horseradish peroxidase conjugate to detect DSG1 protein. (b) Similar to serum
from an FS patient, anti-DSG1 MAbs (FGS-4E4) show typical indirect
immunofluorescence staining patterns using monkey esophagus as the
substrate. Bar in (b)¼ 50mm.
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in the regions encoding FWRs or CDRs, or both. Interestingly,
a comparison of IGHV3-23 and IGHV3-30 sequences
from pre-FS and FS hybridomas reveals multiple shared
amino acid R mutations (Figure 3). The IGHV3-23 mutations
A23T, S31N, S35N, A50S, A50V, S57R, and N74S, as well
as IGHV3-30 mutation, S31N, occurred in both groups.
In addition, the IGHV3-30 mutations, S30R and A88P, each
occurred twice among pre-FS hybridomas. Thus, similar to
FS hybridomas, the pre-FS anti-DSG1 hybridomas exhibit
evidence of selection for mutant B cells, particularly among
anti-DSG1 IgG B cells. Moreover, the shared VH mutations
suggest that the same or a similar antigen is responsible for
the selective pressure in the pre-clinical and clinical stages
of the disease.
DISCUSSION
In this study, we report the genetics of anti-DSG1 auto-
antibodies from eight FS patients and one individual 4 years
before the clinical onset of FS. Our results show that the anti-
DSG1 response in FS patients living in endemic regions of the
disease in Brazil is antigen selected and that selection begins
well in advance of the onset of clinical disease.
The hypothesis of antigen selection of anti-DSG1 B cells in
FS patients is based on several lines of evidence. First,
multiple groups of clonally related hybridomas were identi-
fied among hybridomas from each patient indicating that
certain clones have a selective advantage in growth. Clonally
related hybridoma sets are a characteristic of secondary
responses to foreign antigens (Clarke et al., 1985; Blier and
Bothwell, 1987; Scott et al., 1989) and have been observed
among hybridomas derived from autoimmune patients (Qian
et al., 2007). Second, a limited VH and VL gene repertoire
may be used to encode these anti-DSG1 antibodies in pre-FS
and FS patients. Most VH genes belong to VH families 1, 3,
and 4, similar to those in normal and systemic lupus
erythematosus individuals (Brezinschek et al., 1997; Dorner
et al., 1999; de Wildt et al., 2000). However, IGHV3-23 is
common among IgG anti-DSG1 hybridomas, increasing from
9% among IgM hybridomas to 24% among IgG hybridomas,
suggesting selective pressure in favor of its use in this
response. Selective VL gene use also occurs, as we find that
IGKV1D-39 increases from 8.3% among IgM hybridomas to
23.5% among IgG hybridomas. Thus, V gene use by DSG1-
specific B cells may become increasingly restricted during
the course of the response. Third, FS anti-DSG1 hybridomas
exhibit a bias favoring the accumulation of amino acid R
mutations in CDRs and S mutations in FWRs in either VH or
VL, or both. This pattern is consistent with the selection for R
mutations that provide an advantage in antigen binding
(in CDRs) and against R mutations that could harm antigen
binding or the structural integrity of the antibody molecule
(FWRs). Consistent with this are the numerous parallel VH
mutations among these hybridomas, many of which occurred
in CDRs. Taken together, the anti-DSG1 response of FS
patients resembles antigen-selected responses to foreign
antigen, arguing that the anti-DSG response in FS is antigen
selected. This parallels our findings with the anti-DSG
response in PV (Qian et al., 2007).
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Figure 2. V gene use by fogo selvagem (FS) and pre-FS clonally independent anti-desmoglein 1 (DSG1) hybridomas. (a) VH gene use. (b) VL gene use. IgM
and IgG are summarized separately for FS (upper panels) and pre-FS (lower panels). The number of hybridomas identified by sequence similarity to use
each gene is indicated. Genes used by both FS and pre-FS hybridomas are marked by an asterisk.
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Table 2. L chain V genes of anti-desmoglein 1 (Dsg1) hybridomas from fogo selvagem (FS) patients
FWRs CDRs
PBMC Clones1 Isotype VL Similarity R
2 S3 P 4(FWRs) R S P(CDRs)
FS6 FS6-2C12 IgG1 IGKV1D-39*01 92.4 8 6 0.02417 4 3 0.34897
FS6-2F5(6) IgM IGKV3D-11*01 93.8 5 6 0.01309 3 2 0.35003
FS6-3D7 IgM IGLV3-9*01 97.9 1 2 0.02771 2 1 0.15775
FS6-4A3 IgM IGLV2-14*01 99.3 0 0 0.09251 2 0 0.01514
FS7 FS7-1H10 IgG2 IGKV1D-39*01 96.4 3 2 0.03390 2 3 0.35646
FS7-2F8(4) IgG1 IGKV1D-39*01 96.4 3 3 0.03390 3 1 0.13846
FS8 FS8-1A9 IgM IGKV1D-39*01 96.8 1 2 0.00465 3 2 0.07741
FS12 FS12-1D2(2) IgG1 IGKV3-15*01 97.6 2 1 0.11233 2 1 0.14244
FS12-1F10(2) IgG1 IGLV6-57*01 97.6 3 3 0.34730 0 0 0.84156
FS12-3A7 IgG1 IGLV6-57*01 97.6 3 3 0.34730 0 0 0.84156
FS33 FS33-1B8(4) IgM IGKV3-11*01 98.6 0 1 0.03299 2 0 0.03589
FS33-1D4(2) IgM IGLV1-40*01 99.0 0 1 0.09860 1 0 0.17658
FS33-2E6(4) IgG1 IGKV3-20*01 94.8 3 3 0.00559 4 3 0.10083
FS33-2F4 IgG1 IGKV4-1*01 99.0 2 0 0.61661 1 0 0.29558
FS33-3C7 IgG1 IGLV1-47*01 96.9 2 2 0.04690 2 2 0.28217
FS33-4D4(2) IgM IGKV1-16*01 95.4 4 2 0.06498 5 0 0.0113
FS33-5E11 IgM IGLV1-47*01 100.0
JLDO JLDO-1B2 IgM IGKV1D-17*01 98.9 1 0 0.20091 2 0 0.03448
JLDO-2A3 IgM IGLV2-14*03 97.9 1 1 0.44278 0 0 0.67306
JLDO-3F8 IgG1 IGLV2-11*01 98.6 1 2 0.12676 1 0 0.33844
JLDO-3G4 IgM IGKV3-20*01 97.6 0 2 0.01410 2 0 0.07237
JLDO-4B5 IgG1 IGKV4-1*01 97.7 0 1 0.00818 2 2 0.1599
GCDS GCDS-1C2(2) IgG1 IGKV1-6*01 96.1 4 3 0.06725 3 1 0.15831
GCDS-2A8 IgG1 IGLV2-14*01 97.6 1 3 0.12494 0 0 0.76729
GCDS-2D11 IgG4 IGLV6-57*01 96.5 1 3 0.01293 2 1 0.22925
GCDS-3G9 IgG1 IGKV3-15*01 98.6 0 0 0.03259 3 0 0.00184
GCDS-5D2 IgG1 IGKV3-20*01 98.3 2 2 0.21463 1 0 0.39272
GCDS-6A6 IgG1 IGKV1D-39*01 95.8 1 5 0.00091 4 0 0.03901
GCDS-6G10 IgM IGKV1-5*03 98.2 1 0 0.04899 2 2 0.11176
FGS FGS-4E4(3) IgG4 IGKV1D-33*01 97.2 1 2 0.01021 2 2 0.21164
CDR, complementary determining region; FWR, framework region; PMBC, peripheral blood mononuclear cell.
1Numbers in parentheses indicate the identical clones isolated from the same patient. Clones with evidence of antigen selection in both FWRs and CDRs of
H chains as shown in Table 1 are in bold.
2Number of replacement mutations.
3Number of silent mutations.
4P-value determined according to Lossos et al. (2000). Those values less than 0.05, which are the indication of antigen selection, are shown in bold. FWRs
include FWR1, FWR2, and FWR3, whereas CDRs include CDR1 and CDR2.
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Figure 3. The expressed VH genes from fogo selvagem (FS) and pre-FS hybridomas share replacement mutations. Sequence comparisons were conducted
using Vector NTI (Invitrogen Life Technologies, Carlsbad, CA). All the sequences shown are from independent clones. Complementary determining regions
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The endemic nature of FS, which allowed the freezing of
PBMCs from individuals with a relatively high probability of
developing FS, makes it possible to examine the autoreactive
B-cell repertoire in humans before development of an
autoimmune disease. Our analysis of one pre-FS individual
indicates a remarkable similarity in pre-clinical and clinical
anti-DSG1 responses. Clonal sets of hybridomas were evident
among pre-FS hybridoma panels indicating uneven clonal
expansion. In addition, VH and VL use by pre-FS and FS
hybridomas overlap, particularly with the use of IGHV3-23
and IGHV3-30 (Figure 2a). There is also an overlap in Vk use
by pre-FS and FS hybridomas (6 of 14 Vk genes, Figure 2b).
Although IGKV1D-39 is expressed, it is not dominant, as it is
in the FS response (Figure 2b). The most notable difference
between pre-FS and FS hybridomas is the expression of Vl.
One-third (10 of 29) of the FS hybridomas, but none of the 17
pre-FS hybridomas expressed Vl genes (Figure 2b). Unfortu-
nately, a PBMC sample from this patient after FS diagnosis is
not available. However, the analysis of anti-DSG1 antibodies
in sera from this patient indicates very low levels of l anti-
DSG1 before FS onset compared with after FS diagnosis (data
not shown). In contrast, there was no change in the levels of k
anti-DSG1 before and after active FS. This change in l anti-
DSG1 antibodies was observed in 4 of 11 individuals for
whom sera before and after FS diagnosis were available
(data not shown). This raises the possibility that l anti-DSG
antibodies are a clinical marker for FS that may predict
the development of disease. We are currently testing this
possibility.
The CDR replacement mutations have the most striking
similarity between the pre-FS and FS hybridoma panels. A
total of 18 amino-acid replacement mutations in CDR1 and
CDR2 occurred in IGHV3-23 and IGHV3-30 of pre-FS and FS
hybridomas. In some cases, these mutations occurred multi-
ple times within a panel. We interpret this to mean that many
of the same mutations provide a selective advantage in
the clonal expansion of anti-DSG1 B cells, providing strong
evidence that the same or a similar antigen is responsible for
Table 3. Anti-desmoglein 1 (Dsg1) hybridomas from an individual at preclinical stage of fogo selvagem (FS)
FWRs CDRs
PBMC Clones1 Isotype VH Similarity R
2 S3 P4(FWRs) R S P(CDRs) JH CDR3
Pre-FS FS45-1A3 IgM ND
FS45-1B5 IgM IGHV3-30*18 99.3 1 0 0.42458 1 0 0.17838 IGHJ4*02 DRQLVGHFWTHYFDY
FS45-1B9 IgM IGHV4-4*07 96.6 5 1 0.33430 3 1 0.16242 IGHJ4*02 GWSFFDY
FS45-1C10 IgG1 IGHV4-30-2*01 92.6 8 7 0.03897 6 1 0.15458 IGHJ6*02 GSLSAALKGCAMEV
FS45-1C4 IgM ND
FS45-1C8 IgM IGHV3-11*01 99 1 0 0.03869 1 1 0.27067 IGHJ4*02 GLVQQFSYLPYYFDY
FS45-1G7 IgG1 IGHV5-51*01 96.3 8 0 0.00003 1 2 0.74024 IGHJ4*02 ARVMLHLSGERTFYFDF
FS45-2C6 IgM IGHV3-9*01 98.6 2 1 0.38779 0 1 0.77375 IGHJ6*02 GRYSNSWYGYYSMDV
FS45-2D3 IgM IGHV3-7*01 99.7 0 1 0.21335 0 0 0.59333 IGHJ4*02 LGDY
FS45-3C7 IgG1 IGHV1-69*01 96.6 3 3 0.04427 4 0 0.05014 IGHJ3*01 GPNRRGSYRPNDAFDI
FS45-3C9 IgG1 IGHV3-30-3*01 96.6 4 3 0.10605 2 1 0.32406 IGHJ6*02 TSNWDGLDV
FS45-3E7(6) IgM IGHV3-23*01 95.6 7 2 0.39281 3 1 0.29244 IGHJ4*02 KKAQLSAPFDY
FS45-3H9 IgG1 IGHV4-39*06 96.6 3 1 0.03664 6 1 0.00522 IGHJ4*02 DSAERSELGYFDY
FS45-4A2(2) IgG1 IGHV3-30*18 96.6 4 3 0.14281 3 0 0.17202 IGHJ4*02 RAKWGSPQPYYFDY
FS45-4C7 IgM IGHV1-18*01 96.6 6 1 0.54624 3 0 0.17573 IGHJ6*02 DRDGYNHYYHYGMDV
FS45-4C8 IgG1 IGHV4-31*03 96.7 5 6 0.25173 0 0 0.94877 IGHJ4*02 DLRYNYDYEGSS
FS45-4D5 IgM IGHV3-73*02 81.1 21 19 0.00198 11 5 0.37278 IGHJ4*02 ATRF
FS45-4F11 IgM IGHV1-3*01 99.7 0 1 0.20903 0 0 0.59112 IGHJ6*02 GGLLMTTVTTYYYYYGMDV
FS45-4G1 IgG1 IGHV4-30-2*01 90.4 6 7 0.00086 11 1 0.00191 IGHJ4*02 AGSSYYYDSRGPIDY
FS45-4G4 IgM IGHV1-3*01 92.2 7 6 0.00426 7 3 0.07727 IGHJ3*02 ARRRKSIVVVPAARDDGFDI
FS45-5D3 IgG1 IGHV3-23*04 93.9 4 6 0.00153 7 1 0.01695 IGHJ6*02 DSASPVLYYYYGMDV
FS45-5G6 IgG1 IGHV3-30-3*01 94.5 4 5 0.00518 5 1 0.04133 IGHJ4*02 SVSVRLSHFDH
CDR, complementary determining region; FWR, framework region; ND, not determined; PMBC, peripheral blood mononuclear cell.
1Numbers in parentheses indicate the identical clones isolated. Clones with evidence of antigen selection in both FWRs and CDRs are shown in bold.
2Number of replacement mutations.
3Number of silent mutations.
4P-value determined according to Lossos et al. (2000). Those values less than 0.05, which are the indication of antigen selection, are shown in bold. FWRs
include FWR1, FWR2, and FWR3, whereas CDRs include CDR1 and CDR2.
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clonal selection before and after active FS. The differences
between these responses, such as Vl gene use, may be due to
targeting of different epitopes before and after active FS.
Nevertheless, these data indicate that the selection of anti-
DSG1 B cells begins well before the onset of clinical disease.
What distinguishes between those clones that produce
pathogenic autoantibodies and those that are benign or even
protective has yet to be elucidated, but the current data
suggest that antigen selection of mutant IgG1 anti-DSG1
B cells is not sufficient for pathogenicity, as the pre-FS
individual analyzed here did not develop clinical disease for
another 4 years.
The two IgG4 hybridomas overlap in VH and VL gene use
with IgG1 hybridomas (IGHV3-48, IGHV2-5, and IGLV6-57)
and, similar to IgG1 hybridomas, exhibit a bias in the
distribution of mutations (Table 1). Moreover, the IgG4
hybridoma shares the CDR mutations, Y32F and S53T, with
IgG1 hybridomas (Figure 3). Further analysis of more IgG4
autoantibodies is required to conclusively determine whether
potential pathogenic IgG4 B cells are subject to the same or
similar selective pressures in vivo as IgG1 B cells. Never-
theless, this study provides a view of the anti-DSG1 repertoire
in FS patients indicating that the response to this self-antigen
is antigen selected and begins well in advance of clinical
disease. The source of the driving antigen could be
environmental or self. We previously showed that patients
with parasitic diseases, wherein insect bites are involved,
such as onchocerciasis, leishmaniasis, and Chagas, often
possess serum anti-DSG1 autoantibodies (Diaz et al., 2004).
Epidemiological studies of FS suggest that insect bites are a
risk factor in FS (Aoki et al., 2004). It has been proposed that
arthropod salivary antigen(s) induces the production of cross-
reactive anti-DSG1 antibodies. Alternatively, the inflamma-
tory reaction to insect bites may expose DSG1, allowing an
anti-DSG1 response.
In conclusion, we have shown that the development of
autoantibodies in FS is antigen driven, similar to other
autoimmune diseases, such as systemic lupus erythematosus
and PV, and that antigen selection of anti-DSG1 B cells can
begin years before the onset of active FS.
MATERIALS AND METHODS
Patient samples
Heparinized peripheral blood samples were collected from eight FS
patients and from an individual 4 years before the onset of clinical
FS. All FS patients were living in Limao Verde, Brazil, except three
who were hospitalized in the Penfigo Hospital in Campo Grande,
Brazil. The clinical and serological features of these patients have
Table 4. L chain V genes of anti-desmoglein 1 (Dsg1) hybridomas from a pre-fogo selvagem (FS) individual
FWRs CDRs
PBMC Clones1 Isotype VL Similarity R
2 S3 P4(FWRs) R S P(CDRs)
Pre-FS FS45-1A3 IgM IGKV3-15*01 100.0
FS45-1C10 IgG1 IGKV1-5*03 95.4 3 3 0.01783 1 4 0.70848
FS45-1C4 IgM IGKV1-27*01 98.6 0 2 0.08044 0 0 0.64386
FS45-1C8 IgM IGKV3-15*01 99.6 0 0 0.20121 1 0 0.07719
FS45-1G7 IgG1 IGKV1D-39*01 97.2 2 3 0.05803 2 0 0.20386
FS45-2C6 IgM IGKV2D-28*01 100.0
FS45-2D3 IgM IGKV2-29*02 100.0
FS45-3C7 IgG1 IGKV4-1*01 98.3 1 3 0.06859 0 1 0.83586
FS45-3C9 IgG1 IGKV2D-28*01 99.7 0 0 0.21961 1 0 0.09507
FS45-3E7(3) IgM IGKV3-20*01 98.9 0 0 0.03441 3 0 0.00223
FS45-3H9 IgG1 IGKV4-1*01 99.7 0 0 0.21967 1 0 0.09985
FS45-4C7 IgM IGKV3-11*01 99.7 0 1 0.20203 0 0 0.57947
FS45-4D5 IgM IGKV2D-28*01 100.0
FS45-4F11 IgM IGKV1D-39*01 100.0
FS45-4G4 IgM IGKV1D-39*01 95.8 2 2 0.01459 3 2 0.10611
FS45-5D3 IgG1 IGKV2D-28*01 99.0 1 1 0.24701 0 1 0.73442
FS45-5G6 IgG1 IGKV4-1*01 94.4 5 4 0.04315 5 1 0.11207
CDR, complementary determining region; FWR, framework region; PMBC, peripheral blood mononuclear cell.
1Numbers in parentheses indicate the identical clones isolated. Clones with evidence of antigen selection in both FWRs and CDRs of H chains as shown in
Table 3 are in bold.
2Number of replacement mutations.
3Number of silent mutations
4P-value determined according to Lossos et al. (2000). Those values less than 0.05, which are the indication of antigen selection, are shown in bold. FWRs
include FWR1, FWR2, and FWR3, whereas CDRs include CDR1 and CDR2.
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been reported previously, that is, FS6 (patient no. 6), FS7 (patient no.
7), FS8 (patient no. 8), and FS 12 (patient no. 12) (Hans-Filho et al.,
1996). FS33 is a patient from Limao Verde who developed FS at age
44 and was not included in the previous report. The patient donating
blood 4 years before the onset of disease was FS45 who developed
FS at age 22 and is the son of FS12 and brother of FS46. Patient JLDO
was a 23-year-old female with a 5-month history of generalized FS.
Patient GCDS was a 13-year-old male with a 1-year history of
generalized FS. Finally, FGS was a 33-year-old female with a
5-month history of generalized FS. All patient samples and clinical
information were collected with written informed consent and
adherence to the Helsinki Guidelines. All experiments were
approved by the Institutional Review Boards of the University of
North Carolina and the University of Sao Paulo, Brazil.
Cell preparation and hybridoma generation
Hybridomas were generated by fusion of Epstein-Barr virus-
transformed PBMCs with mouse myeloma cells (P3X63Ag8.653)
(Kumpel, 2000) or MFP-2S myeloma cells (Kalantarov et al., 2002),
as described previously (Qian et al., 2007). MFP-2S myeloma cells
were kindly provided by Drs Kalantarov and Trakht from Columbia
University, New York, USA. Hybridomas secreting anti-DSG1
antibodies were screened using a DSG1-specific ELISA, as described
previously (Warren et al., 2000, 2003; Li et al., 2003; Diaz et al.,
2004). The specificity of these autoantibodies was confirmed by
immunoprecipitation (Warren et al., 2000; Li et al., 2003) and
indirect immunofluorescence using monkey esophagus (IF) as
described (Anhalt et al., 1982; Ding et al., 1997).
Sequence analysis of VH and VL region from cloned hybridoma
cells
Messenger RNA isolation, PCR amplification, and sequence analysis
were conducted as described previously (Qian et al., 2007). The
distribution of somatic mutations was analyzed according to the
multinomial distribution model established by Lossos et al. (2000)
and the P-values were calculated using the JAVA applet at http://
www-stat.stanford.edu/immunoglobin. A P-value of less than 0.05 is
taken as evidence for antigen selection at FWR and CDR (Lossos
et al., 2000).
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